by Nathaniel Harding | Mar 11, 2024 | Blog
Cortado Ventures is thrilled to have recently invested in Cadenza Bio, an Oklahoma life sciences company developing novel therapeutic drugs to treat demyelinating, inflammatory, and neurodegenerative diseases, with a first indication in multiple sclerosis (MS). Read...
by Nathaniel Harding | Feb 22, 2024 | Blog
A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad Cortado is thrilled to invest in CorriXR Therapeutics, an early-stage biotech company commercializing a platform gene editing technology with a first-use case in oncology. The novel approach seeks to...
by Nathaniel Harding | Feb 5, 2024 | Blog, Media
Lumata Health: Pioneering Next-Generation Eye Care At Cortado Ventures, we are in the venture capital business of maximizing risk-adjusted returns with high-potential, early-stage startups. We seek transformative technology solutions with as little risk as possible....
by Nathaniel Harding | Feb 1, 2024 | Blog
2023 Lookback for Cortado Ventures At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and most innovative startups. Let’s...
by Nathaniel Harding | Jan 4, 2024 | Blog
Preclinical biotechnology company initially focusing on therapeutic drug development to promote remyelination in Multiple Sclerosis OKLAHOMA CITY, Dec. 14, 2023 /PRNewswire/ — Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on...
by Nathaniel Harding | Nov 2, 2023 | Blog
At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi...
